Brokerages Set Celldex Therapeutics, Inc. (NASDAQ:CLDX) Price Target at $66.00

Celldex Therapeutics, Inc. (NASDAQ:CLDX) has received an average recommendation of “Moderate Buy” from the six ratings firms that are covering the firm, MarketBeat reports. One investment analyst has rated the stock with a hold recommendation and five have issued a buy recommendation on the company. The average 1 year target price among analysts that have updated their coverage on the stock in the last year is $63.00.

Several equities research analysts have commented on CLDX shares. Guggenheim raised their price target on shares of Celldex Therapeutics from $72.00 to $90.00 and gave the company a “buy” rating in a research note on Tuesday, February 27th. HC Wainwright restated a “buy” rating and issued a $80.00 price target on shares of Celldex Therapeutics in a research note on Monday, June 3rd. Cantor Fitzgerald restated an “overweight” rating and issued a $67.00 price target on shares of Celldex Therapeutics in a research note on Friday, March 22nd. Finally, Wolfe Research started coverage on shares of Celldex Therapeutics in a research note on Tuesday, June 11th. They issued an “outperform” rating and a $51.00 price target on the stock.

Insider Activity

In other news, VP Elizabeth Crowley sold 38,597 shares of the stock in a transaction that occurred on Thursday, May 30th. The shares were sold at an average price of $33.64, for a total value of $1,298,403.08. Following the completion of the transaction, the vice president now directly owns 9,074 shares in the company, valued at $305,249.36. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. In other news, VP Elizabeth Crowley sold 38,597 shares of the stock in a transaction that occurred on Thursday, May 30th. The shares were sold at an average price of $33.64, for a total value of $1,298,403.08. Following the completion of the transaction, the vice president now directly owns 9,074 shares in the company, valued at $305,249.36. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, SVP Diane C. Young sold 45,000 shares of the firm’s stock in a transaction that occurred on Friday, June 7th. The stock was sold at an average price of $35.26, for a total transaction of $1,586,700.00. Following the sale, the senior vice president now owns 2,115 shares of the company’s stock, valued at $74,574.90. The disclosure for this sale can be found here. Insiders sold 219,160 shares of company stock worth $7,501,489 over the last three months. Corporate insiders own 3.80% of the company’s stock.

Institutional Trading of Celldex Therapeutics

A number of large investors have recently added to or reduced their stakes in CLDX. Price T Rowe Associates Inc. MD boosted its holdings in Celldex Therapeutics by 631.1% during the first quarter. Price T Rowe Associates Inc. MD now owns 3,087,208 shares of the biopharmaceutical company’s stock worth $129,571,000 after buying an additional 2,664,915 shares in the last quarter. Eventide Asset Management LLC boosted its holdings in Celldex Therapeutics by 126.9% during the fourth quarter. Eventide Asset Management LLC now owns 3,630,013 shares of the biopharmaceutical company’s stock worth $143,966,000 after buying an additional 2,030,013 shares in the last quarter. Point72 Asset Management L.P. boosted its holdings in Celldex Therapeutics by 105.3% during the fourth quarter. Point72 Asset Management L.P. now owns 2,756,122 shares of the biopharmaceutical company’s stock worth $109,308,000 after buying an additional 1,413,722 shares in the last quarter. Wellington Management Group LLP boosted its holdings in Celldex Therapeutics by 19.2% during the fourth quarter. Wellington Management Group LLP now owns 6,476,561 shares of the biopharmaceutical company’s stock worth $256,860,000 after buying an additional 1,044,728 shares in the last quarter. Finally, Jennison Associates LLC boosted its stake in Celldex Therapeutics by 3,327.0% in the 1st quarter. Jennison Associates LLC now owns 688,080 shares of the biopharmaceutical company’s stock worth $28,879,000 after purchasing an additional 668,002 shares during the period.

Celldex Therapeutics Stock Down 4.8 %

CLDX opened at $34.67 on Tuesday. The firm has a market cap of $2.29 billion, a price-to-earnings ratio of -12.16 and a beta of 1.47. Celldex Therapeutics has a fifty-two week low of $22.11 and a fifty-two week high of $53.18. The company’s 50-day moving average price is $37.76 and its 200 day moving average price is $38.94.

Celldex Therapeutics (NASDAQ:CLDX) last released its quarterly earnings data on Monday, May 6th. The biopharmaceutical company reported ($0.56) earnings per share for the quarter, topping the consensus estimate of ($0.67) by $0.11. The firm had revenue of $0.16 million for the quarter, compared to analyst estimates of $1.30 million. Celldex Therapeutics had a negative net margin of 2,385.57% and a negative return on equity of 29.55%. Research analysts anticipate that Celldex Therapeutics will post -2.32 earnings per share for the current year.

Celldex Therapeutics Company Profile

Celldex Therapeutics, Inc, a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases.